How to buy Adaptive Biotechnologies stock (ADPT)

Adaptive Biotechnologies is a biotechnology business based in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.97 – a decrease of 3.08% over the previous week. Adaptive Biotechnologies employs 709 staff and has a trailing 12-month revenue of around $177.3 million.

Our top picks for where to buy Adaptive Biotechnologies stock

Buy Adaptive Biotechnologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Adaptive Biotechnologies stock price (NASDAQ: ADPT)

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.97
52-week range	$2.28 - $7.07
50-day moving average more info button	$5.42
200-day moving average more info button	$4.18
Wall St. target price	$7.58
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.34

Is it a good time to buy Adaptive Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptive Biotechnologies price performance over time

Historical closes compared with the close of $6.52 from 2024-12-17

1 week (2024-12-12)	5.84%
1 month (2024-11-20)	47.51%
3 months (2024-09-19)	36.40%
6 months (2024-06-18)	111.69%

1 year (2023-12-19)	28.85%
2 years (2022-12-19)	-10.19%
3 years (2021-12-17)	29.2
5 years (2019-12-19)	30.24

Adaptive Biotechnologies financials

Revenue TTM	$177.3 million
Gross profit TTM	$-13,657,000
Return on assets TTM	-16.37%
Return on equity TTM	-66.76%
Profit margin	-110.13%
Book value	$1.52
Market Capitalization more info button	$881 million

TTM: trailing 12 months

Adaptive Biotechnologies share dividends

We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.

Adaptive Biotechnologies share price volatility

Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as $2.28 up to $7.0665. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 1.447. This would suggest that Adaptive Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Adaptive Biotechnologies overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.

Frequently asked questions

null
What percentage of Adaptive Biotechnologies is owned by insiders or institutions?
Currently 1.926% of Adaptive Biotechnologies shares are held by insiders and 93.921% by institutions. How many people work for Adaptive Biotechnologies?
Latest data suggests 709 work at Adaptive Biotechnologies. When does the fiscal year end for Adaptive Biotechnologies?
Adaptive Biotechnologies's fiscal year ends in December. Where is Adaptive Biotechnologies based?
Adaptive Biotechnologies's address is: 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 What is Adaptive Biotechnologies's ISIN number?
Adaptive Biotechnologies's international securities identification number is: US00650F1093 What is Adaptive Biotechnologies's CUSIP number?
Adaptive Biotechnologies's Committee on Uniform Securities Identification Procedures number is: 00650F109